SEC Form 4 · accession 0001209191-18-029726
Travere Therapeutics, Inc. · TVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John A Orwin
Director
Period of report
May 9, 2018
Accepted (ET)
May 11, 2018 · 9:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001438533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 9, 2018 | A | 2,500 | $0.00 | A | 6,875 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $26.52 | May 9, 2018 | A | 10,000 | A | — | May 8, 2028 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1The option shall vest in 4 equal quarterly installments following the date of grant.